Drug Profile
Research programme: amino acyl-tRNA synthetases - aTyr Pharma
Alternative Names: Amino acyl-tRNA synthetase splice variants - aTyr Pharma; AspRSlN1 (C76S); DRS1-154 (C76S); Homeokine; Phe-tRNA Synthetase; Physiocrines - aTyr Pharma; Resected amino acyl-tRNA synthetase - aTyr Pharma; Tmax; Tyrosyl-tRNA SynthetaseLatest Information Update: 13 Oct 2022
Price :
$50
*
At a glance
- Originator aTyr Pharma
- Class Amino acyl-tRNA synthetases; Angiogenic proteins; Anti-inflammatories; Biological proteins; Proteins
- Mechanism of Action Angiogenesis inducing agents; Cytokine receptor modulators; Enzyme replacements; G protein-coupled receptor modulators; Histidine-tRNA ligase modulators; Toll-like receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Charcot-Marie-Tooth disease; Immunological disorders; Inflammation; Metabolic disorders; Thrombocytopenia
Most Recent Events
- 11 Oct 2022 aTyr Pharma and Dualsystems Biotech enter into a research collaboration for tRNA synthetases
- 28 Sep 2022 No recent reports of development identified for preclinical development in Immunological-disorders in USA
- 01 Feb 2021 aTyr Pharma terminates its research collaboration and option agreement with CSL Behring for development of tRNA synthetase based therapeutics